New agents for gout provide alternatives to allopurinol.(RHEUMATOLOY): An article from: Internal Medicine News
This digital document is an article from Internal Medicine News, published by International Medical News Group on January 15, 2009. The length of the article is 788 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details
Title: New agents for gout provide alternatives to allopurinol.(RHEUMATOLOY)
Author: Nancy Walsh
Publication: Internal Medicine News (Magazine/Journal)
Date: January 15, 2009
Publisher: International Medical News Group
Volume: 42 Issue: 2 Page: 13(1)
Distributed by Gale, a part of Cengage Learning
List Price: $ 9.95
Price: $ 9.95
New agents for gout provide alternatives to allopurinol.(RHEUMATOLOY): An article from: Internal Medicine News
Febuxostat, allopurinol jockey for role in gout.(MUSCULOSKELETAL DISORDERS): An article from: Family Practice News
This digital document is an article from Family Practice News, published by International Medical News Group on October 1, 2009. The length of the article is 1440 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details
Title: Febuxostat, allopurinol jockey for role in gout.(MUSCULOSKELETAL DISORDERS)
Author: Mitchel L. Zoler
Publication: Family Practice News (Magazine/Journal)
Date: October 1, 2009
Publisher: International Medical News Group
Volume: 39 Issue: 17 Page: 30(2)
Distributed by Gale, a part of Cengage Learning
List Price: $ 9.95
Price: $ 9.95
Febuxostat, allopurinol jockey for role in gout.(MUSCULOSKELETAL DISORDERS): An article from: Family Practice News
Related Allopurinol For Gout Products
Orignal From: New agents for gout provide alternatives to allopurinol.(RHEUMATOLOY): An article from: Internal Medicine News Reviews
No comments:
Post a Comment